| Literature DB >> 34189094 |
Fang Liu1, Xiaoli Luo2, Xiuqi Chen3, Zhenhao Lu4, Dan Wei3, Zhiyong Yang3.
Abstract
BACKGROUND: N-terminal brain natriuretic peptide precursor (NT-proBNP) and brain natriuretic peptide (BNP) are mainly produced and secreted in the heart. In 2008, the European Heart Association recommended that serum BNP/NT-proBNP levels should be included in one of the diagnostic criteria of heart failure. Serum NT-proBNP is more stable than BNP, and the detection results are less affected by objective factors, so it is widely used. At present, NT-proBNP has long been beyond the scope of heart failure markers, and has a wide range of clinical value in the evaluation and prediction of some serious diseases. This study prospectively studied the predictive value of serum NT-proBNP in pediatric intensive care unit (PICU).Entities:
Keywords: N-terminal brain natriuretic peptide precursor (NT-proBNP); Pediatric intensive care unit (PICU); children; prediction
Year: 2021 PMID: 34189094 PMCID: PMC8192984 DOI: 10.21037/tp-21-123
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
Comparison of sex, age, weight, and BMI among the three groups
| Group | Non-risk group (n=127) | Risk group (n=150) | High-risk group (n=98) | χ2/F value | P |
|---|---|---|---|---|---|
| Gender, n (%) | 2.095 | 0.351a | |||
| Male | 71 (55.9) | 89 (59.3) | 49 (50.0) | ||
| Female | 56 (44.1) | 61(40.7) | 49 (50.0) | ||
| Age (years) | 2.33 (0.33–8.67) | 1.38 (0.5–5.37) | 2.13 (0.5–7.5) | 0.686 | 0.710b |
| Weight (kg) | 10 (5.4–21) | 9.15 (6.58–16.88) | 12 (6.3–21) | 0.877 | 0.645b |
| BMI (kg/m2) | 14.49 (13.22–16.26) | 15.21 (13.60–16.93) | 15.27 (13.56–16.89) | 4.472 | 0.107b |
a, refers to the chi-square test; b, refers to the rank sum test of multiple independent samples.
Comparison of NT-proBNP levels among the three groups
| Group | NT-proBNP, M (P25–P75) |
|---|---|
| Non-risk group | 564.6 (128.3–1,863)*# |
| Risk group | 722.1 (250.93–2,872.5)* |
| High-risk group | 2,716 (687.58–18,793.75) |
| χ2 | 41.765 |
| P | <0.001a |
a, the chi-square test; b, the rank sum test of two independent samples. Compared with the high-risk group, *P<0.001; compared with the risk group, #P=0.013.
Comparison of mortality rate among three groups
| Group | Non-survivors (n=42) | Survivors (n=333) | P |
|---|---|---|---|
| Non-risk group | 6 (4.72%) | 121 (95.28%) | 0.196 |
| Risk group | 13 (8.67%) | 137 (91.33%) | <0.001 |
| High risk group | 23 (23.47%) | 75 (76.53%) | <0.001 |
| χ2 | 21.156 | ||
| P | <0.001a | ||
Figure 1ROC curve of serum NT-proBNP levels for predicting the critical degree stage of the patient. 94 mm ×132 mm (96 × 96 DPI). NT-proBNP, N-terminal brain natriuretic peptide precursor.
Binary logistical regression analysis of the 28-day mortality endpoint
| Index | B | S.E. | Wald | P | OR | 95% confidence interval |
|---|---|---|---|---|---|---|
| NT-proBNP | 0.000 | 0.000 | 0.109 | 0.741 | 1.000 | 1.000–1.000 |
| PCT | −0.005 | 0.007 | 0.620 | 0.431 | 0.995 | 0.981–1.008 |
| Mechanical ventilation time | 0.000 | 0.001 | 0.077 | 0.782 | 1.000 | 0.998–1.002 |
| PCIS score | −0.013 | 0.035 | 0.138 | 0.710 | 0.987 | 0.921–1.057 |
| PRISM III score | 0.068 | 0.036 | 3.663 | 0.056 | 1.071 | 0.998–1.148 |
| SOFA score | 0.233 | 0.084 | 7.721 | 0.005 | 1.263 | 1.071–1.489 |
| Number of MODS | 0.323 | 0.282 | 1.304 | 0.253 | 1.381 | 0.794–2.402 |